Evidence map›Paper›PMID 41271850›Full record

ArticleScientific reports2025

Proinflammatory markers in women with type 1 diabetes and polycystic ovary syndrome.

Manuel Ramón García-Sáenz, Nitzia López-Juárez, Jorge Valencia-Ortega, Renata Saucedo, Miry Lobaton-Ginsberg, Claudia Ramirez-Renteria, Kapy Leon-Wu, Ernesto Sosa-Eroza, Etual Espinosa-Cárdenas, Aldo Ferreira-Hermosillo

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manuel Ramón García-SáenzServicio de Endocrinología, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Nitzia López-JuárezServicio de Endocrinología, Hospital de Cardiología del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Jorge Valencia-OrtegaDepartamento de Patología, Centro Médico Naval, Mexico City, Mexico.
Renata SaucedoUnidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Miry Lobaton-GinsbergUnidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Claudia Ramirez-RenteriaUnidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Kapy Leon-WuServicio de Endocrinología, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Ernesto Sosa-ErozaServicio de Endocrinología, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Etual Espinosa-CárdenasServicio de Endocrinología, Hospital de Especialidades del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Aldo Ferreira-HermosilloUnidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. aferreira@endocrinologia.org.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The frequency of polycystic ovary syndrome (PCOS) appears to be higher in women living with type 1 diabetes (T1D). Both diseases are characterized by a mild chronic inflammatory state. The proinflammatory protein profile in this population has not been fully evaluated. We conducted a cross-sectional, exploratory study in patients at the T1D Clinic from a tertiary referral hospital in Mexico. Using stored samples from a previous cohort, we categorized patients with T1D with or without PCOS, overweight/obesity, and metabolic syndrome (MS). C-reactive protein (CRP), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-a) levels were quantified and compared among the groups. Thirty-seven patients were analyzed. IL-6 levels were greater in the groups with T1D and overweight or obesity than in the group with a normal body mass index (p = 0.003) and were greater in the group with T1D and MS than in the group with T1D without MS (p = 0.029). No differences were observed among patients with T1D with or without PCOS. Post-hoc power analysis indicated high power (> 95%) to detect clinically relevant differences in CRP and IL-6, but low power (26%) for TNF-a. In this exploratory study of women with T1D, obesity and other components of MS appeared more important determinants of inflammation than PCOS, probably because of the different pathophysiology of PCOS in these patients and the dominant inflammatory effect of adiposity.

Indexed as

BiomarkersDiabetes Mellitus, Type 1Polycystic Ovary SyndromeAdultBody Mass IndexC-Reactive ProteinCross-Sectional StudiesFemaleHumansInflammationInterleukin-6Metabolic SyndromeMexicoObesityTumor Necrosis Factor-alphaYoung AdultBiomarkersC-Reactive ProteinInterleukin-6Tumor Necrosis Factor-alphaInterleukinsMetabolic syndromeObesityPolycystic ovary syndromeTumor necrosis factor alpha

Identifiers

PMID41271850
PMCPMC12638899

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.